别名 45, X syndrome、45,X syndrome、45,X/46,XX syndrome + [92] |
简介 A syndrome of defective gonadal development in phenotypic females associated with the karyotype 45,X (or 45,XO). Patients generally are of short stature with undifferentiated GONADS (streak gonads), SEXUAL INFANTILISM, HYPOGONADISM, webbing of the neck, cubitus valgus, elevated GONADOTROPINS, decreased ESTRADIOL level in blood, and CONGENITAL HEART DEFECTS. NOONAN SYNDROME (also called Pseudo-Turner Syndrome and Male Turner Syndrome) resembles this disorder; however, it occurs in males and females with a normal karyotype and is inherited as an autosomal dominant. |
靶点 |
作用机制 NPRB激动剂 |
非在研适应症- |
最高研发阶段批准上市 |
首次获批国家/地区 欧盟 [+3] |
首次获批日期2021-08-26 |
靶点 |
作用机制 GR激动剂 |
非在研适应症 |
最高研发阶段批准上市 |
首次获批国家/地区 美国 |
首次获批日期2021-08-25 |
靶点 |
作用机制 GHR激动剂 |
在研机构 |
原研机构 |
最高研发阶段批准上市 |
首次获批国家/地区 美国 |
首次获批日期2020-08-28 |
开始日期2024-12-01 |
申办/合作机构- |
开始日期2024-03-01 |
开始日期2024-02-28 |